Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DAO Supplementation for IBS Symptoms
NCT06139744Phase 4Unknown
- Sponsor
- Nanjing First Hospital
- Start
- Nov 2023
- Primary completion
- Aug 2024
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial (2 arms), sponsored by Nanjing First Hospital. Primary endpoint: IBS Severity Scoring System at 4 weeks. Status: unknown.
Beyond the preview
Go deeper on NCT06139744.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06139744.